| Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073) | ArriVent BioPharma, Inc. | 2022-06-30 |
| A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) (NCT05546905) | Pierre Fabre Medicament | 2022-06-23 |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (NCT05429320) | Memorial Sloan Kettering Cancer Center | 2022-06-15 |
| Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (NCT05226598) | Merck Sharp & Dohme LLC | 2022-03-24 |
| Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT04743505) | Washington University School of Medicine | 2022-01-18 |
| Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy (NCT05111197) | Institut Cancerologie de l'Ouest | 2022-01-12 |
| Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment (NCT05167500) | Fundación GECP | 2021-12-09 |
| A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC (NCT05236608) | National University Hospital, Singapore | 2021-11-12 |
| Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (NCT04884282) | Fondazione Ricerca Traslazionale | 2021-10-12 |
| Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib (NCT05675683) | Novartis Pharmaceuticals | 2021-10-01 |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) (NCT04965090) | Memorial Sloan Kettering Cancer Center | 2021-09-30 |
| Dupilumab_Metastatic NSCLC (NCT05013450) | Thomas Marron | 2021-09-10 |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (NCT04614103) | Iovance Biotherapeutics, Inc. | 2021-05-07 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (NCT04863248) | G1 Therapeutics, Inc. | 2021-04-30 |
| Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) (NCT04725188) | Merck Sharp & Dohme LLC | 2021-04-20 |
| Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (NCT04685135) | Mirati Therapeutics Inc. | 2021-02-23 |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (NCT04623775) | Bristol-Myers Squibb | 2021-02-17 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596) | Mirati Therapeutics Inc. | 2020-12-02 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations (NCT04511533) | Pfizer | 2020-08-27 |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers (NCT04410796) | Memorial Sloan Kettering Cancer Center | 2020-05-28 |
| Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC (NCT05278052) | Tata Memorial Hospital | 2020-04-20 |
| Plasma-Adapted First-Line Pembro In NSCLC (NCT04166487) | Julia K. Rotow, MD | 2020-01-13 |
| Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA (NCT03926260) | Centre Hospitalier Departemental Vendee | 2019-06-27 |
| Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) (NCT03976375) | Merck Sharp & Dohme LLC | 2019-06-26 |
| Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer (NCT03810807) | Memorial Sloan Kettering Cancer Center | 2019-01-17 |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) (NCT03679767) | Incyte Corporation | 2019-01-09 |
| A Study of ADXS-NEO Expressing Personalized Tumor Antigens (NCT03265080) | Advaxis, Inc. | 2018-03-28 |
| PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients (NCT03436056) | Royal Marsden NHS Foundation Trust | 2018-03-01 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer (NCT03215810) | H. Lee Moffitt Cancer Center and Research Institute | 2017-10-11 |
| UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. (NCT03224871) | University of California, Davis | 2017-08-11 |
| SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (NCT03004183) | The Methodist Hospital Research Institute | 2017-07-01 |
| Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC (NCT03300115) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2017-05-18 |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (NCT02857270) | Eli Lilly and Company | 2016-09-29 |
| PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer (NCT02793856) | Sichuan University | 2016-08-26 |
| Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy (NCT02705820) | Bank of Cyprus Oncology Centre | 2016-04-25 |
| Universal Cancer Peptide-based Vaccination in Metastatic NSCLC (NCT02818426) | Centre Hospitalier Universitaire de Besancon | 2016-04-20 |
| Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer (NCT02639234) | Gradalis, Inc. | 2016-03-01 |
| Abscopal Effect for Metastatic Non-small Cell Lung Cancer. (NCT02542930) | Zhejiang Provincial People's Hospital | 2016-01-01 |
| A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (NCT02411448) | Eli Lilly and Company | 2015-05-06 |
| Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC (NCT02330367) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2015-01-01 |
| Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (NCT01936961) | Western Regional Medical Center | 2013-06-01 |
| Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT01395758) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2011-07-01 |
| Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients (NCT01717105) | Grupo Gallego de Cancer de Pulmon | 2011-03-01 |
| CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] (NCT06585189) | Aetion, Inc. | 2010-02-01 |
| Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer (NCT01060514) | Northwestern University | 2010-02-01 |
| A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases (NCT00872482) | YM BioSciences | 2009-04-01 |
| Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer (NCT00806286) | Daiichi Sankyo | 2008-12-01 |
| Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer (NCT04599712) | Janssen Research & Development, LLC | |